Evidence map›Paper›PMID 40023516›Full record

ArticleMolecular pharmacology2025

Dual nuclear receptor 4A1 (NR4A1/NR4A2) ligands inhibit glioblastoma growth and target TWIST1.

Srijana Upadhyay, Miok Lee, Lei Zhang, Arafat Rahman Oany, Svetlana A Mikheeva, Andrei M Mikheev, Robert C Rostomily, Stephen Safe

Abstract read
In one paragraph

Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Srijana UpadhyayDepartment of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Texas A&M University, College Station, Texas.
Miok LeeDepartment of Biochemistry and Biophysics, College of Agricultural and Life Sciences, Texas A&M University, College Station, Texas.
Lei ZhangDepartment of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Texas A&M University, College Station, Texas.
Arafat Rahman OanyDepartment of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Texas A&M University, College Station, Texas.
Svetlana A MikheevaDepartment of Neurosurgery, Houston Methodist Hospital and Research Institute, Houston, Texas.
Andrei M MikheevDepartment of Neurosurgery, Houston Methodist Hospital and Research Institute, Houston, Texas.
Robert C RostomilyDepartment of Neurosurgery, Houston Methodist Hospital and Research Institute, Houston, Texas.
Stephen SafeDepartment of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Texas A&M University, College Station, Texas. Electronic address: ssafe@cvm.tamu.edu.

Funding

Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Sakhila Banu · 2019 to 2026
$13.0M
“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”R01NS129720 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Andrei M Mikheev, ROBERT C ROSTOMILY · 2023 to 2026
$2.1M
NIEHS NIH HHS P30 ES029067NINDS NIH HHS R01 NS129720
6 · The paper itself

Abstract

1,1-Bis(3'-indolyl)-1-(3,5-disubstitutedphenyl)methane (DIM-3,5) compounds are dual receptor ligands that bind both orphan nuclear receptor 4A1 (NR4A1) and NR4A2. Knockdown of NR4A1 or NR4A2 by RNA interference in glioblastoma (GBM) cells decreased growth and induced apoptosis and comparable effects were observed for DIM-3,5 analogs, which exhibit inverse agonist activity and inhibit NR4A1- and NR4A2-mediated pro-oncogenic activity. Knockdown of NR4A1 or NR4A2 or treatment with DIM-3,5 analogs also decreased expression of TWIST1 mRNA and protein in GBM cells by 40%-90%.The proximal region of the TWIST1 gene promoter contains functional GC-rich binding sites that bind Sp1 and Sp4, and knockdown of these transcription factors also decreased TWIST1 expression in GBM cells. Further analysis by chromatin immunoprecipitation, protein-protein coimmunoprecipitation, and binding assays demonstrated that NR4A1/NR4A2 coregulate TWIST1 gene expression as ligand-dependent cofactors of Sp1 and Sp4, which interact with cis proximal GC-rich sites in the TWIST1 gene promoter. In vivo studies show that DIM-3,5 dual NR4A1/2 inverse agonists also reduced intratumoral TWIST1 expression while significantly prolonging survival of mice in a syngeneic mouse model of GBM, demonstrating that these ligands are promising new agents for targeting TWIST1 and treating GBM. SIGNIFICANCE STATEMENT: The TWIST1 gene is a pro-oncogenic factor that regulates epithelial-to-mesenchymal transition in glioblastoma cells. This paper shows that the orphan nuclear receptor 4A1 (NR4A1) and NR4A2 regulate TWIST1 expression, which can be targeted by bis-indole-derived dual NR4A1/2 inverse agonists.

Indexed as

GlioblastomaIndolesNuclear ProteinsNuclear Receptor Subfamily 4, Group A, Member 1Nuclear Receptor Subfamily 4, Group A, Member 2Twist-Related Protein 1AnimalsApoptosisCell Line, TumorCell ProliferationHumansLigandsMiceMice, NudeXenograft Model Antitumor AssaysIndolesLigandsNR4A1 protein, humanNR4A2 protein, humanNuclear ProteinsNuclear Receptor Subfamily 4, Group A, Member 1Nuclear Receptor Subfamily 4, Group A, Member 2TWIST1 protein, humanTwist-Related Protein 1AnticarcinogenicGBMNR4A1NR4A2TWIST1

Identifiers

PMID40023516
PMCPMC11881746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.